Evidence map›Paper›PMID 41912871›Full record

ArticleEMBO molecular medicine2026

A monocyte-centered framework for predicting immunochemotherapy efficacy in lung squamous cell carcinoma patients.

Jiangnan Zhao, Zijin Wang, Manyu Xiao, Yeyuan Zhang, Boxin Liu, Silin Chen, Yiping Tian, Dongqing Lv, Pingli Wang, Hai Song and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EMBO molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Jiangnan Zhao *Department of Respiratory and Critical Care Medicine, the Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, 322000, China.
Zijin Wang *Centre for Infection Immunity and Cancer (IIC) of Zhejiang University-University of Edinburgh Institute (ZJU-UoE Institute), Department of Respiratory and Critical Care Medicine, the Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, 310029, China.ORCID 0009-0004-7856-3601
Manyu Xiao *Centre for Infection Immunity and Cancer (IIC) of Zhejiang University-University of Edinburgh Institute (ZJU-UoE Institute), Department of Respiratory and Critical Care Medicine, the Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, 310029, China.ORCID 0009-0000-0307-0096
Yeyuan ZhangDepartment of Respiratory and Critical Care Medicine, the Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, 322000, China.
Boxin LiuCentre for Infection Immunity and Cancer (IIC) of Zhejiang University-University of Edinburgh Institute (ZJU-UoE Institute), Department of Respiratory and Critical Care Medicine, the Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, 310029, China.ORCID 0009-0005-8509-0133
Silin ChenCentre for Infection Immunity and Cancer (IIC) of Zhejiang University-University of Edinburgh Institute (ZJU-UoE Institute), Department of Respiratory and Critical Care Medicine, the Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, 310029, China.
Yiping TianDepartment of Pathology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, China.
Dongqing LvDepartment of Respiratory and Critical Care Medicine, Taizhou Hospital of Zhejiang Province of Wenzhou Medical University, Taizhou, 317000, China.
Pingli WangDepartment of Respiratory and Critical Care Medicine, the Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, 310052, China.
Hai SongDepartment of Respiratory and Critical Care Medicine, the Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, 322000, China.ORCID 0000-0002-7081-9308
Yuefeng WuWestlake Laboratory of Life Sciences and Biomedicine, School of Life Sciences, Westlake University, Hangzhou, Zhejiang, 310030, China.
Jian LiuCentre for Infection Immunity and Cancer (IIC) of Zhejiang University-University of Edinburgh Institute (ZJU-UoE Institute), Department of Respiratory and Critical Care Medicine, the Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, 310029, China. JianL@intl.zju.edu.cn.ORCID 0000-0002-1447-0973
Kai WangDepartment of Respiratory and Critical Care Medicine, the Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, 322000, China. kaiw@zju.edu.cn.ORCID 0000-0003-4328-8799

Funding

Key R&D Program of Zhejiang Grant No. 2025C02091Medical Scientific Research Foundation of Zhejiang Province, China Grant No. WKJ-ZJ-2508MOST | National Key Research and Development Program of China (NKPs) 2024YFA1108500MOST | National Natural Science Foundation of China (NSFC) General Grant: 82172899 and 82472637MOST | National Natural Science Foundation of China (NSFC) U23A20467MOST | NSFC | NSFC-Zhejiang Joint Fund | | Natural Science Foundation of Zhejiang Province (ZJNSF) Continuation Grant of Distinguished Young Scholars: RG26H160003MOST | NSFC | NSFC-Zhejiang Joint Fund | | Science Fund for Distinguished Young Scholars of Zhejiang Province () Distinguished Young Scholars: LR22H160002Noncommunicable Chronic Diseases-National Science and Technology Major Project 2023ZD0502900/ 2023ZD0502902 and 2023ZD0507500/2023ZD0507501Noncommunicable Chronic Diseases-National Science and Technology Major Project 2024ZD0529300
6 · The paper itself

Abstract

Lung cancer is the leading cause of cancer-related mortality worldwide, with lung squamous cell carcinoma (LUSC) comprising 20-30% of cases. Immunochemotherapy (IC) is the standard first-line treatment for advanced LUSC, yet reliable predictors of therapeutic response remain unavailable. Using single-cell multi-omics profiling of paired pre- and post-treatment tumor and blood samples, we observed that patients responding to IC exhibited significantly higher baseline levels of peripheral blood monocytes, tumor-infiltrating classical monocytes, and APOBEC3A+ monocytes across both compartments compared with non-responders. These associations were independently validated in additional cohorts using routine complete blood count testing and multiplex immunofluorescence analysis of native tumor tissues. Our findings reveal monocyte-related parameters as clinically accessible indicators that link systemic immunity with the tumor microenvironment and hold promise for predicting IC responsiveness in patients with LUSC.

Indexed as

Carcinoma, Squamous CellImmunotherapyLung NeoplasmsMonocytesCytidine DeaminaseFemaleHumansMaleTreatment OutcomeTumor MicroenvironmentCytidine DeaminaseAPOBEC3ABiomarkerImmunochemotherapyMonocytesPredictor

Identifiers

PMID41912871
PMCPMC13179367

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.